NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis

BioCryst Pharmaceuticals, Inc. (BCRX) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

BCRX

$9.96

−$0.13 (−1.29%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BCRX with… →

BCRX Key Statistics

As of Sep 4, 2026
Trading
Open
$10.00
Previous Close
$10.09
Day's Range
9.90–10.10
52-Week Range
6.00–11.22
Volume
1.48M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.56
Valuation
Market Cap
$2.55B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
10.60
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
9.39
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.71
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.38
Financials (FY)
Revenue (FY)
$874.84M+94.10%
Net Income (FY)
$263.86M
Profit marginThe share of revenue left as profit after all costs and taxes.
−40.90%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
255.54M
1-Year Return
+20.44%
Dividend and dates
Earnings Date
November 2, 2026
Avg Volume
4.29M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BCRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+27.69%
2025+3.72%
2024+25.54%
2023−47.82%
2022−17.11%
2021+85.91%
2020+115.94%
2019−57.25%
2018+64.36%
2017−22.43%
2016 (partial year)+51.07%

As of September 4, 2026.

BCRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$874.84M$263.86M30.2%
2024$450.71M−$88.88M−19.7%
2023$331.41M−$226.54M−68.4%
2022$270.83M−$247.12M−91.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$874.84M$855.76M$340.99M$263.86M30.2%
2024$450.71M$438.44M−$2.54M−$88.88M−19.7%
2023$331.41M$326.93M−$103.71M−$226.54M−68.4%
2022$270.83M$264.23M−$148.44M−$247.12M−91.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BCRX Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricBCRXDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio2.712.3018% above
Profit margin−40.90%−3.14%37.8 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BioCryst Pharmaceuticals, Inc. (BCRX) is capitalised at $2.55B on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 435.

Over the past 52 weeks the price has ranged from $6.00 to $11.22. The most recent close on file for BCRX is $9.96, dated September 4, 2026. That is −$0.13 (−1.29%) against the previous close. The latest close sits 66% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $874.84M. Against the prior fiscal year total of $450.71M, that is a change of +94.10%. Net income for the same year was $263.86M. The reported profit margin is −40.9%. That is 37.8 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −1.38.

Across the 4 fiscal years on file, revenue moves from $270.83M in 2022 to $874.84M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 10.6. The PEG ratio, which sets the P/E against expected earnings growth, reads 9.39. The price-to-sales ratio is 2.71. On price-to-sales that is 17.83% above the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.56. Daily returns over the trailing 10 years annualize to a volatility of 72.21%. The trailing one-year price return is +20.44%. Across 10 years the annualized return works out at +9.02%.

Growth & Income

The record shows no dividend for BCRX.

Across the complete calendar years on file, 2020 returned +115.94% and 2019 returned −57.25%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is +27.69%.

Peer Comparison

BioCryst Pharmaceuticals, Inc. (BCRX) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BioCryst Pharmaceuticals, Inc. BCRX $2.55B —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. BioCryst Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Visit website →